Table 7 Adverse events observed in the study population
Group A (n = 31) (Peg-IFNα + RBV + placebo) | Group B (n = 31) (Peg-IFNα + RBV + Silybin, Vit E, phospholipids) | P Value | |
|---|---|---|---|
Psychological disorders | 14% | 12% | NS |
Hypercholesterolemia | 16% | 32% | P < 0.01 |
Fatigue | 48% | 44% | NS |
Headache | 41% | 42% | NS |
Musculoskeletal pain | 54% | 35% | P < 0.01 |
Myalgia | 58% | 32% | P < 0.01 |
Hypertriglyceridemia | 44% | 30% | P < 0.01 |
Nausea | 31% | 24% | P < 0.05 |
Anorexia | 6% | 8% | NS |
Irritability | 30% | 22% | P < 0.05 |
Hyperglycemia | 13% | 8% | P < 0.05 |
Weight loss | 12% | 7% | P < 0.05 |
Decrease of hemoglobin values at the end of treatment | from 13.6 g/dL (range 11.4–14.4) to 11.6 g/dL (range 10.4–14.2 g/dL) | from 13.6 g/dL (range 11.6–15.9 g/dL) to 10.6 (range 10.4–12.8 g/dL) | NS |